ACHVNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
ACHIEVE LIFE SCIENCES, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026
$6.61+0.23 (+3.53%)
Close on Oct 19, 2026
- Market cap
- $617.64M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
+$2.41 (+57.26%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $617.64M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- -8.01%
Fundamentals
- Net income
- -$114.04M
- EPS, diluted
- -$1.54
- Free cash flow
- -$49.47M
- Book value per share
- -$0.16
- Diluted shares
- 94M
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
–
Net income
-$114.04M
EPS, diluted
-$1.54
Free cash flow
–
Reported periodTrailing twelve months